Be the first person to write a business review for Quest PharmaTech Inc.

Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Union City, California. Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company, provides prescription drugs for central nervous system disorders. The company markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy; and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

Quintiles Transnational has plenty to CRO about. One of the world's top contract research organizations (CROs), with operations in more than 50 countries, it helps drug and medical device companies develop and sell their products. The firm provides a comprehensive range of clinical trials management services, including patient recruitment, data analysis, laboratory testing, and regulatory filing. Its consulting unit offers strategic advice at every stage of drug discovery and development, and its Innovex subsidiary is a contract sales organization providing sales personnel to promote approved products. An investment group led by founder and CEO Dennis Gillings owns the company.

Radiant Research is aglow with success. The contract research organization (CRO) conducts late phase human clinical trials for drugmakers and medical device makers at a network of some 25 research facilities that it owns across the US. Its services run the gamut from early Phase IIb trials all the way to post-approval Phase IV testing for new therapies in areas including cardiology, infectious diseases, asthma and allergies, and women's health. Radiant recruits the participants for the trials as well as gathers data for the companies; it also provides study design, consulting, and analysis services. Clients include major pharmaceutical companies, as well as biotech and medical device companies.

ReGen Therapeutics did. Its main product is Colostrinin, a polypeptide derived from ovine and bovine colostrum (the first milk produced after the birth of an offspring). The company developed a nutraceutical version of the product that its licensee Metagenics launched in the US under the name CogniSure in 2007. ReGen continues development of a pharmaceutical preparation, as well as a veterinary nutraceutical version for pets. In addition to Colostrinin, ReGen is developing existing insomnia drug Zolpidem as a treatment for head trauma victims. The company's Guildford Clinical Pharmacology subsidiary is a UK-based contract research organization.

Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York. Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company's commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical trials include Aflibercept for the treatment of oncology; VEGF Trap-Eye in wet AMD in patients for eye diseases; and ARCALYST versus placebo for the prevention of gout flares in patients initiating urate-lowering drug therapy. The company's products under clinical trials include REGN88, an antibody to the Interleukin-6 receptor (IL-6R) that is being evaluated in patients with rheumatoid arthritis; REGN421, an antibody to delta-like ligand-4 that is being developed for oncology; and REGN475, an antibody to nerve growth factor, which is being developed for the treatment of pain. Regeneron Pharmaceuticals also conducts other preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, and cardiovascular diseases. The company has strategic collaboration agreements with sanofi-aventis Group to discover, develop, and commercialize fully human monoclonal antibodies; and Bayer HealthCare LLC for the development of the VEGF-Trap-Eye.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.